CLASS ACTION UPDATE for CDNA, ET and TDOC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

[ACCESSWIRE]

NEW YORK, NY / ACCESSWIRE / July 1, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

CDNA Shareholders Click Here: https://www.zlk.com/pslra-1/caredx-inc-information-request-form?prid=29503&wire=1
ET Shareholders Click Here: https://www.zlk.com/pslra-1/energy-transfer-lp-loss-submission-form?prid=29503&wire=1
TDOC Shareholders Click Here: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-submission-form?prid=29503&wire=1

* ADDITIONAL INFORMATION BELOW *

CareDx, Inc. (NASDAQ:CDNA)

This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.
Lead Plaintiff Deadline: July 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/caredx-inc-information-request-form?prid=29503&wire=1

According to the filed complaint, (1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company's RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company's testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Energy Transfer LP (NYSE:ET)

This lawsuit is on behalf of persons who purchased or otherwise acquired common shares of Energy Transfer stock between April 13, 2017 and December 20, 2021, both dates inclusive.
Lead Plaintiff Deadline: August 2, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/energy-transfer-lp-loss-submission-form?prid=29503&wire=1

According to the filed complaint, (a) Energy Transfer had inadequate internal controls and procedures to prevent contractors from engaging in illegal conduct with regards to drilling activities, and/or failed to properly mitigate known issues related to such controls and procedures; (b) Energy Transfer, through its subsidiary Rover Pipeline, LLC, hired a third-party contractor to conduct Horizontal Directional Drilling Activities for the Rover Pipeline Project, whose conduct of adding illegal additives in the drilling mud caused severe pollution near the Tuscarawas River when a large inadvertent release took place on April 13, 2017; (c) Energy Transfer continually downplayed its potential civil liabilities when the Federal Energy Regulatory Commission ("FERC") was actively investigating the Energy Transfer's wrongdoing related to the April 13 release and consistently provided it with updated information about FERC's findings on this matter.

Teladoc Health, Inc. (NYSE:TDOC)

TDOC Lawsuit on behalf of: investors who purchased October 28, 2021 - April 27, 2022
Lead Plaintiff Deadline: August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-submission-form?prid=29503&wire=1

According to the filed complaint, during the class period, Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) increased competition, among other factors, was negatively impacting Teladoc's BetterHelp and chronic care businesses; (ii) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (iii) as a result, Teladoc's revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (iv) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP